Status:
UNKNOWN
A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage
Lead Sponsor:
Charite University, Berlin, Germany
Collaborating Sponsors:
Pfizer
Aventis Pharmaceuticals
Conditions:
Small Cell Lung Cancer
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
PHASE3
Brief Summary
Comparison of two combination chemotherapies in the treatment of patients with SLCL
Detailed Description
Comparison of two combination chemotherapies in the treatment of patients with SLCL The combination chemotherapies for this study are Carboplatin plus Irinotecan versus Carboplatin plus Etoposide.
Eligibility Criteria
Inclusion
- cytological or histological proven SCLC Stage I or II at 1st diagnosis
- no prior chemotherapy
- measurable tumor disease
- karnofsky performance 70
Exclusion
- second malignancy ( except basal cell carcinoma, CA in situ Cervix uteri)
- NYHA III
- chronic diarrhea, obstructive bowel syndrome
Key Trial Info
Start Date :
October 1 2001
Trial Type :
INTERVENTIONAL
End Date :
December 1 2006
Estimated Enrollment :
286 Patients enrolled
Trial Details
Trial ID
NCT00168896
Start Date
October 1 2001
End Date
December 1 2006
Last Update
February 14 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hematology & Oncology Charité CBF Berlin, Germany
Berlin, State of Berlin, Germany, 12203